Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Another nebulous RNS very disappointing will sell on that news but having read the brokers note will hold fire for any further news as I understand the interims were 6 months up to June 30th
“applying both existing and new technologies for patient selection “ Hopefully they might be considering AI might boost the SP !
Clutching at straws
P
Https://www.sciencemediacentre.org/expert-reaction-to-review-of-commercial-clinical-trials-in-the-uk-by-lord-oshaughnessy/
Will it be of benefit to Synairgen or is it just more platitudes ?
Https://www.bbc.co.uk/news/technology-66394406
Lemos mentioned
Https://www.bmj.com/content/381/bmj.p1306
Interesting BMJ article ref metformin
Jeremy Faust from Harvard Medical School, who was not involved in the research, said the findings, if confirmed, are “profound and potentially landmark.”
Didn't Prof Chris Brightling say something similar about Synairgen's Long Covid Data last year ?Another boat of oportuniy missed
"Wonder if our government would see fit to get on that band wagon.."
Very sobering item on Newsnight this evening featuring the UK chip industry including Nexperia/China concerns .Ref was made to IQE and its technologies photonics and LIDAR Then an interview with Hermann Hauser , he was asked whether Jeremy Hunt has any chance of creating a UK Silicon Valley. His answer was " Zero". The only big players with the money and the skills are the US , China and Europe and since Brexit leaving the EU is now just a minnow within the global industry What ever Hermann thinks I still believe in British innovation and our universities which he was a product of , Acorn and oak trees spring to mind LOL
Out of interest I noted that BARDA mentioned a call for the treatments for sepsis and after watching that very sad documentary about Jason Watkins 's daughter Maude who he sadly lost through sepsis .The disease has a similar reaction to a cytokine storm in covid patients and I wondered if beta interferon would be of benefit as a Host Directed therapeutic/ immunomodulator /broad spectrum antiviral/antibiotic
https://www.frontiersin.org/articles/10.3389/fimmu.2017.00493/full#:~:text=IFN-%CE%B2%20is%20an%20essential%20cytokine%20in%20promoting%20and,as%20a%20therapeutic%20strategy%20for%20human%20sepsis%20%285%29.
https://openres.ersjournals.com/content/9/2/00605-2022
Very confused with the Sprinter Results seems like Raw Data to me and annoying trolls chipping in with their off the cuff interpretations .Wait a minute why am listening to them! In response I have posted the link to the peer review reported in the ERJ open Research for all those who were dismayed reading the those results. The peer review gives greater insight from the scientists in our Synairgen team ATB
Drive appears to me to replicate the primary and secondary objectives in the Universal Trial , phenotypic characterisation
patient Stratification not too sure about endotyping but it is used in the taxonomy of COPD and Asthma . The data from Universal could be very significant to provide the heads up sngoo1 for any potential trial including Drive ?